logo

For the Inventor, By the Inventor

Kenilworth, NJ, United States of America

Smartcells, Inc.


USPTO Granted Patents = 19



Forward Citations = 96

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Todd C Zion (19 out of 49 patents)

silverMedal Thomas M Lancaster (19 out of 49 patents)

bronzeMedal Wenyi Cai (2 out of 2 patents)

4.  Ryan Faucette (2 out of 2 patents)

5.  Matthew Pecukonis (2 out of 2 patents)

6.  Sylaja Murikipudi (1 out of 3 patents)

7.  Rassol Laleau (1 out of 1 patent)

8.  Robert Butters (1 out of 1 patent)

9.  Naomi Choodnovskiy (1 out of 1 patent)

10.  Zhiyu Chen (1 out of 1 patent)

11.  Matthew Nalewanski (1 out of 1 patent)


19 patents:

1. 10398781 - Conjugate based systems for controlled drug delivery (2019-09-03),
2. 9745355 - Binding-site modified lectins and uses thereof (2017-08-29),
3. 9579391 - Conjugate based systems for controlled drug delivery (2017-02-28),
4. 9463249 - Crystalline insulin-conjugates (2016-10-11),
5. 9265838 - Conjugate based systems for controlled drug delivery (2016-02-23),
6. 9114176 - Exogenously triggered controlled release materials and uses thereof (2015-08-25),
7. 9095623 - Terminally-functionalized conjugates and uses thereof (2015-08-04),
8. 9074015 - Recombinantly expressed insulin polypeptides and uses thereof (2015-07-07),
9. 9068013 - Recombinant lectins, binding-site modified lectins and uses thereof (2015-06-30),
10. 9050370 - Conjugate based systems for controlled drug delivery (2015-06-09),
11. 8933207 - Drug-ligand conjugates, synthesis thereof, and intermediates thereto (2015-01-13),
12. 8906850 - Crystalline insulin-conjugates (2014-12-09),
13. 8846103 - Exogenously triggered controlled release materials and uses thereof (2014-09-30),
14. 8729242 - Methods for reducing the mitogenicity of lectin compositions (2014-05-20),
15. 8697643 - Method for controllably releasing a drug conjugate within subcutaneous tissue in response to the local concentration of an indicator (2014-04-15),
Company Overview
Smartcells, Inc. is a biotechnology company based in Kenilworth, NJ, specializing in the development of innovative solutions for diabetes management. The organization focuses on creating advanced insulin delivery systems that enhance the quality of life for individuals with diabetes. By leveraging cutting-edge research in biochemistry and materials science, Smartcells aims to improve the efficacy and convenience of insulin therapies, contributing to better health outcomes in the diabetes community.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Smartcells, Inc. USPTO Patent Assignee Logo
19 Patents

#3 in Kenilworth, NJ

#648 in New Jersey

#17,150 in US

#32,693 in the World

Kenilworth, NJ (US)
Kenilworth, NJ, United States of America

Smartcells, Inc.

Forward Citations = 96

11 inventors:

goldMedal Todd C Zion (19 out of 49 patents)

silverMedal Thomas M Lancaster (19 out of 49 patents)

bronzeMedal Wenyi Cai (2 out of 2 patents)

4.  Ryan Faucette (2 out of 2 patents)

5.  Matthew Pecukonis (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Smartcells, Inc.. Retrieved from https://idiyas.com/company/smartcells

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…